Is Alcon still part of Novartis?
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
Does Novartis own Alcon?
Novartis acquired Alcon in 2011 from Nestle for $52 billion. When Alcon was acquired by Novartis, the company’s business focus included surgical equipment, eye drugs and products such as contact lenses and eye drops.
Does Nestle own Novartis?
Nestlé completes its acquisition of Novartis Medical Nutrition.
Is Alcon a medical device company?
Alcon is the largest eye care device company in the world. We operate in the ophthalmic surgical and vision care markets, which are large, dynamic and growing.
What brands does Alcon own?
Whatever your eye care need, Alcon has a solution….EYE VITAMINS
- SYSTANE® ICAPS® Eye Vitamin Softgels. Give your eyes the extra vitamins and minerals they need for vision health with easy-to-digest softgels.
- SYSTANE® ICAPS® Eye Vitamin Chewables.
- SYSTANE® ICAPS® Eye Vitamin Tablets.
Where is Novartis located in the US?
Cambridge, MA
Cambridge, MA, USA (Headquarters) The headquarters is home to research in the areas of oncology, ophthalmology, and cardiovascular and metabolic-related diseases.
What are the ratings of Alcon and Novartis?
Moody’s Investor Service and S&P Global Ratings have rated Alcon at Baa2 and BBB, respectively, with a stable outlook. Bank of America Merrill Lynch and UBS AG are advising Novartis on the transaction. Shares of Novartis will continue to trade on the SIX under the symbol “NOVN”.
Is Alcon a publicly traded company?
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities. Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off.
What happens to Novartis ADRs when Alcon shares are distributed?
Any holders of Novartis ADRs who sell them “regular-way” prior to the close of trading on April 8, 2019 will also be forfeiting their right to receive Alcon shares in the distribution.
What are the conditions precedent for the Alcon spin-off?
Basel, March 22, 2019 – Novartis today confirmed that certain important conditions precedent for the 100% spin-off of the Alcon eye care business have been met, including receipt of certain necessary authorizations and rulings.